ClinicalTrials.gg
CompletedNCT00742963Updated May 13, 2025Results posted

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

A Phase 1/2 interventional study of TH-302 in Soft Tissue Sarcoma, sponsored by ImmunoGenesis. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by ImmunoGenesis · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
144th of 800
107 · median 35
Started
2008
with 27 others
Phase 1/2
112 of 958
28 open now
Registered
295th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 144th largest by enrollment of the 800 interventional ones that give a count, is one of 28 that started in 2008, is one of 112 in phase 1/2, and was the 295th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.

Read the detailed description

A broad range of tumors have been shown to contain significant numbers of hypoxic cells and hypoxia has been shown to be associated with a poor prognosis and an increase in resistance to chemotherapy and radiotherapy (Brizel 1997, Vaupel 2007, Shannon 2003).

It is likely that an agent that could effectively target hypoxic regions in tumors would improve efficacy when combined with standard chemotherapy or radiotherapy. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies. This should result in an improved therapeutic ratio (tumor vs normal tissue toxicity) as compared with other bioreductive agents. Because TH-302 is expected to be minimally toxic to aerobic cancer cells, optimal efficacy would be expected when TH-302 is combined with treatments that are most effective under aerobic conditions such as radiotherapy and cytotoxic chemotherapy. Preclinical data have shown at least additive efficacy when TH-302 is combined with chemotherapy. In order to minimize the risk of additive toxicity, TH-302 is not being evaluated in combination with alkylating agents. The study will enroll subjects with advanced soft tissue sarcoma. These tumors have evidence supporting the presence of hypoxia based on pO2 histography, F-MISO and gene expression profiling (Vaupel 2007, Francis 2007, Rajendran 2003).

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • TH-302
  • Advanced Soft Tissue Sarcoma
  • Doxorubicin
  • Phase 1/2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects:

  • At least 18 years of age
  • Ability to understand the purposes and risks of the study and has signed a written form approved by the investigator's IRB/Ethics Committee
  • confirmed diagnosis of soft tissue sarcoma of the following subtypes:
  • Synovial sarcoma
  • High grade fibrosarcoma
  • Unclassified, undifferentiated sarcoma
  • Liposarcoma
  • Leiomyosarcoma (excluding GIST)
  • Angiosarcoma (excluding Kaposi's sarcoma)
  • Pleomorphic sarcoma/malignant fibrous histiocytoma
  • Locally advanced unresectable or disease with no standard curative therapy available and for whom treatment with single agent doxorubicin is considered appropriate; subjects in the dose escalation cohorts must have progressed since their most recent systemic therapy
  • Recovered from reversible toxicities of prior therapy
  • Evaluable disease by criteria (at least one target or non-target lesion for dose escalation cohorts; at least 1 target lesion for dose expansion cohort)
  • performance status of 0 or 1
  • of at least 3 months
  • Acceptable liver function:
  • ≤ 1.5 times (ULN)
  • (SGOT) and ALT (SGPT) ≤ 2.5 times ULN
  • Acceptable renal function:
  • Serum creatinine within normal limits
  • Acceptable hematologic status (without hematologic support):
  • ≥ 1500 cells/μL
  • count ≥ 100,000/μL
  • ≥ 9.0 g/dL
  • Acceptable cardiac function:
  • Normal 12-lead (clinically insignificant abnormalities permitted)
  • normal by MUGA or echocardiogram
  • Urinalysis: No abnormalities
  • All women of must have a negative serum pregnancy test and all subjects must agree to use effective means of (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose

Exclusion criteria

Exclusion Criteria

Prior therapy:

  • Dose escalation cohort: Prior treatment with more than 2 myelosuppressive cytotoxic chemotherapy regimens
  • Expanded cohort: Prior systemic therapy for advanced disease ( and adjuvant permitted)
  • Low grade tumors according to standard grading systems (eg AJCC Grade 1 and 2)
  • Prior therapy with ifosfamide or cyclophosphamide
  • Prior therapy with an anthracycline or anthracenedione
  • Prior mediastinal/cardiac radiotherapy
  • Current use of drugs with known cardiotoxicity or known interactions with doxorubicin (see product label)
  • Anticancer treatment with radiation therapy, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), immunotherapy, hormones or other antitumor therapies within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)
  • Significant cardiac dysfunction:
  • Any history of congestive heart failure
  • Any history of transmural myocardial infarction
  • Uncontrolled arrhythmias within the past 6 months
  • Angina pectoris requiring antianginal medication within the past 6 months
  • valvular heart disease
  • Poorly controlled hypertension within the last 6 months
  • Seizure disorders requiring anticonvulsant therapy
  • Known (unless previously treated and well controlled for a period of ≥ 3 months) Previously treated , except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
  • Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause normal tissue hypoxia
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Prior therapy with an hypoxic cytotoxin
  • Subjects who participated in an drug or device study within 28 days prior to study entry
  • Known infection with , , or
  • Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH-302
  • Females who are pregnant or breast-feeding
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  • Unwillingness or inability to comply with the study protocol for any reason
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    1

    75 mg/m2 of Doxorubicin administered by bolus injection starting on Day 1 of a 21-day cycle.

    Drug: TH-302

Interventions

  • DrugTH-302

    TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle. Dose escalation dose levels: Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) Measured of TH-302 When Used in Combination With Doxorubicin and Prophylactic Growth Factor Support in Subjects With Advanced Soft Tissue Sarcoma

    Time frame: Two years

07

Results

Posted Sep 25, 2017

Participant flow

Participant flow — Overall Study
MilestoneTH-302 in Combination With Doxorubicin
Started101
Completed all treatment cycles68
Completed68
Not completed33

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) Measured of TH-302 When Used in Combination With Doxorubicin and Prophylactic Growth Factor Support in Subjects With Advanced Soft Tissue Sarcoma
Time frame:
Two years
Reported as:
Number · mg/m2
Maximum Tolerated Dose (MTD) Measured of TH-302 When Used in Combination With Doxorubicin and Prophylactic Growth Factor Support in Subjects With Advanced Soft Tissue Sarcoma
mg/m2TH-302 in Combination With Doxorubicin
Maximum Tolerated Dose (MTD) Measured of TH-302 When Used in Combination With Doxorubicin and Prophylactic Growth Factor Support in Subjects With Advanced Soft Tissue Sarcoma300

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TH-302 in Combination With Doxorubicin—64/101 (63.4%)101/101 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventTH-302 in Combination With Doxorubicin
Febrile neutropeniaBlood and lymphatic system disorders6/101
PyrexiaGeneral disorders4/101
NeutropeniaBlood and lymphatic system disorders3/101
Abdominal painGastrointestinal disorders3/101
Neutropenic infectionInfections and infestations2/101
Septic shockInfections and infestations2/101
AnaemiaBlood and lymphatic system disorders2/101
ThrombocytopeniaBlood and lymphatic system disorders2/101
Deep vein thrombosisVascular disorders2/101
Abdominal pain upperGastrointestinal disorders2/101
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTH-302 in Combination With Doxorubicin
NauseaGastrointestinal disorders75/101
AnaemiaBlood and lymphatic system disorders72/101
FatigueGeneral disorders70/101
AlopeciaSkin and subcutaneous tissue disorders54/101
ThrombocytopeniaBlood and lymphatic system disorders53/101
StomatitisGastrointestinal disorders49/101
ConstipationGastrointestinal disorders46/101
AnorexiaMetabolism and nutrition disorders40/101
DiarrhoeaGastrointestinal disorders37/101
VomitingGastrointestinal disorders36/101

Baseline characteristics

107 enrolled, 101 dosed.

Age, Categorical
Age, Categorical(Participants)TH-302 in Combination With Doxorubicin
<=18 years0
Between 18 and 65 years77
>=65 years24
Sex: Female, Male
Sex: Female, Male(Participants)TH-302 in Combination With Doxorubicin
Female58
Male43
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TH-302 in Combination With Doxorubicin
American Indian or Alaska Native0
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American7
White86
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)TH-302 in Combination With Doxorubicin
United States101
08

Study locations

9 sites
  • Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Stanford University
    Stanford, California 94305, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46204, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washingon University Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • Mary Crowley Cancer Research Centers
    Dallas, Texas 75201, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jul 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2008
First posted
Aug 28, 2008
Start
Aug 2008
Primary completionActual
Jul 2013
CompletionActual
Oct 2013
Results first posted
Sep 25, 2017
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00742963
Lead sponsor
ImmunoGenesis
Responsible party
Sponsor
First posted
Aug 28, 2008
Start date
Aug 2008
Primary completion
Jul 2013
Completion
Oct 2013
Results posted
Sep 25, 2017
Last update
May 13, 2025

Study contacts

Kristen Ganjoo, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TH 302

Start the discussion